Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Rozanolixizumab

Aliases
UCB7665

12 clinical trials

6 indications

Indication
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Indication
Immune Thrombocytopenia
Indication
Myasthenia Gravis
Indication
MOG-AD
Indication
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Indication
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Clinical trial
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)
Status:
Clinical trial
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Status: Terminated, Estimated PCD: 2022-12-21
Clinical trial
An Open-Label Extension Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Status: Completed, Estimated PCD: 2024-01-25
Clinical trial
An Open-label, Crossover Study to Evaluate Rozanolixizumab Self-administration by Study Participants With Generalized Myasthenia Gravis
Status: Active (not recruiting), Estimated PCD: 2024-04-24
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3, Pivotal Study With an Open-Label Extension Period to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD)
Status: Recruiting, Estimated PCD: 2026-08-10
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Status: Active (not recruiting), Estimated PCD: 2025-02-14
Clinical trial
A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Status: Completed, Estimated PCD: 2021-09-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Status: Completed, Estimated PCD: 2021-08-31
Clinical trial
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Status: Terminated, Estimated PCD: 2022-03-21
Clinical trial
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status: Completed, Estimated PCD: 2021-11-10
Clinical trial
A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Status: Terminated, Estimated PCD: 2022-04-25
Clinical trial
A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Status: Completed, Estimated PCD: 2021-03-31